methyl 5-(4-fluorophenyl)hexanoate | 260059-61-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 5-(4-fluorophenyl)hexanoate
• CAS: 260059-61-8
• 化学式: C₁₃H₁₇FO₂
• 分子量: 224.275
• InChiKey: FADDHPDMFWHUTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-(4-Fluorophenyl)-hexanoic acid 在 conc. sulphuric acid 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 以97%的产率得到methyl 5-(4-fluorophenyl)hexanoate
  参考文献：
  名称：

  US6552223

  摘要：

  公开号：

文献信息

• N-HYDROXYACYLAMINO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：AstraZeneca AB

  公开号：EP1109777A1

  公开（公告）日：2001-06-27
• US6552223B1
  申请人：——

  公开号：US6552223B1

  公开（公告）日：2003-04-22
• [EN] N-HYDROXYACYLAMINO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] COMPOSES N-HYDROXYACYLAMINO, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：ZENECA LTD

  公开号：WO2000012467A1

  公开（公告）日：2000-03-09

  Compounds of the formula (I): R1-CO-N(OH)-CR?2R3-CR4R5¿-CONH-CR?6R7-CONR8R9¿, wherein R1 is C¿1-6?alkyl, aryl or aryl C1-6alkyl; R?2¿ is hydrogen, C¿1-6?alkyl, C3-8cycloalkyl, aryl or arylC1-6alkyl; R?3¿ is hydrogen, C¿1-6?alkyl or arylC1-6alkyl; or R?2 and R3¿; together with the carbon atom to which they are joined, form a C¿3-8?cycloalkyl ring; R?4¿ is hydrogen, C¿1-6?alkyl or aryl C1-6alkyl; R?5¿ is hydrogen, C¿1-6?alkyl or arylC1-6alkyl; R?6¿ is hydrogen, C¿1-6?alkyl, C2-6alkenyl, C3-8cycloalkylC1-6alkyl, arylC1-6alkyl, heteroarylC1-6alkyl or the side-chain of a naturally occuring amino acid; R?7¿ is hydrogen or C¿1-6?alkyl; R?8¿ is hydrogen, C¿1-6?alkyl, C3-8cycloalkyl, C3-8cycloalkenyl, arylC1-6alkyl, heteroarylC1-6alkyl or heterocyclyC1-6alkyl; R?9¿ is hydrogen or C¿1-6?alkyl; or R?8 and R9¿, together with the nitrogen atom to which they are joined, form a heterocyclic ring; wherein any group or ring in R1-R9 is optionally substituted; and pharmaceutically-acceptable salts and in vivo hydrolysable precursors thereof, are inhibitors of one or more metalloproteinase enzymes and therefore are useful in treating various disease conditions including inflammatory and allergic diseases.